DEA Seeks to Ban Psychedelics While FDA Accelerates Approval of Promising Therapies

A significant regulatory conflict has emerged as the FDA holds historic hearings to advance psychedelic-assisted therapies for mental health conditions, while the DEA simultaneously moves to restrict several psychedelic substances. The FDA's efforts aim to expedite clinical development and patient access to these compounds, which show strong promise for treating treatment-resistant depression, PTSD, and anxiety disorders. This divergence highlights ongoing tension between federal agencies regarding psychedelic research classification and therapeutic potential. Patient advocates and researchers argue that the DEA's restrictive approach undermines legitimate medical advancement and delays access to potentially life-changing treatments.